Does Regence Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 receptor alpha subunit, shutting down both IL-4 and IL-13 signaling, the two cytokines most responsible for the type 2 inflammatory cascade seen in atopic dermatitis, asthma, and related conditions. The FDA first approved dupilumab in March 2017 for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies. Since then, the label has expanded seven times.

Why Specialty Biologics Require Special Handling

Dupixent is classified as a specialty biologic by virtually every commercial insurer, including Regence. Specialty drugs carry their own formulary tier, separate distribution rules (usually through a specialty pharmacy rather than a retail chain), and their own prior authorization (PA) pathway. The word "specialty" signals to a health plan that the drug costs more than $600 per month, requires clinical monitoring, or has a narrow indicated population.

Because Dupixent's 2024 wholesale acquisition cost (WAC) runs approximately $3,080 per injection and most patients inject every two weeks, annual spend approaches $37,000 before any rebates. Regence, like other Blue Cross plans, negotiates confidential rebates with Sanofi, so the plan's actual cost is lower, but the list price explains why a utilization management program exists at all.

The Seven FDA-Approved Indications That May Trigger Coverage

Coverage rules differ by indication. Regence medical policy documents typically mirror the FDA label, so a claim submitted for an off-label use will almost certainly be denied. The current on-label indications, according to the FDA prescribing information, are:

• Moderate-to-severe atopic dermatitis (adults, adolescents 12+, children 6 months and older)
• Moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid dependence
• Chronic rhinosinusitis with nasal polyposis (CRSwNP)
• Eosinophilic esophagitis (EoE), ages 12 and older weighing at least 40 kg
• Prurigo nodularis
• Alopecia areata (moderate-to-severe)
• COPD with type 2 inflammation (added 2024)

A 2023 systematic review in the Journal of the American Academy of Dermatology noted that dupilumab's mechanism provides clinically meaningful improvement across all type 2 inflammatory diseases, confirming biological plausibility for each approved indication. See the trial data summarized in the SOLO 1 and SOLO 2 registrational trials published in the New England Journal of Medicine.

How Regence's Prior Authorization Process Works for Dupixent

Prior authorization is not optional for Dupixent on Regence plans. The PA requirement applies to commercial fully-insured plans, self-funded plans that have adopted Regence's standard utilization management criteria, and Regence Medicare Advantage products. Understanding the specific criteria ahead of time reduces back-and-forth with the insurance company by weeks.

Standard PA Criteria for Atopic Dermatitis

For the most common indication, moderate-to-severe atopic dermatitis, Regence typically requires all of the following before approving Dupixent:

1. A confirmed diagnosis of atopic dermatitis documented in the clinical chart with severity classified as moderate or severe (IGA score of 3 or 4, or EASI score of 16 or higher).
2. Documentation that the patient tried and failed at least one topical corticosteroid of medium-to-high potency for a minimum of four weeks.
3. Documentation that a topical calcineurin inhibitor (tacrolimus 0.1% or pimecrolimus 1%) was tried and failed or is contraindicated.
4. The prescriber is a board-certified dermatologist or an allergist/immunologist.
5. No active, untreated bacterial, viral, or parasitic infection that would be worsened by IL-4/IL-13 blockade.

Some Regence plan variants also ask for a trial of systemic therapy (cyclosporine, methotrexate, or mycophenolate mofetil) before approving Dupixent, though this requirement is increasingly being waived given the hepatotoxicity and nephrotoxicity profiles of those older immunosuppressants. The 2023 American Academy of Dermatology guidelines explicitly state that physicians should not be required to cycle through systemic immunosuppressants before accessing biologics in moderate-to-severe disease. Review the full AAD-NPF guidelines on atopic dermatitis management.

Standard PA Criteria for Asthma

For moderate-to-severe asthma, Regence follows criteria aligned with the GINA 2023 report and FDA labeling. Requirements typically include:

• Confirmed asthma diagnosis with FEV1/FVC ratio below 0.70 on spirometry.
• Blood eosinophil count of 150 cells/mcL or higher at baseline, or documented oral corticosteroid dependence.
• Inadequate control on at least one medium-to-high dose inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA).
• Prescriber must be a pulmonologist, allergist, or internist with documented asthma expertise.

The LIBERTY ASTHMA QUEST trial (N=1,902) showed that dupilumab 200 mg every 2 weeks reduced severe asthma exacerbations by 47.7% versus placebo (P<0.001) in patients with baseline eosinophils at or above 300 cells/mcL. The full results are available at PubMed. Citing this trial directly in a PA letter meaningfully strengthens the clinical argument.

How Long PA Approval Lasts

Initial PA approvals for Dupixent on Regence plans are typically granted for 12 months. After that, the prescriber must submit a PA renewal demonstrating clinical response, usually defined as a 50% or greater improvement in IGA, EASI, or symptom score compared to baseline. Patients who fail to show documented response may face non-renewal, at which point the prescriber should appeal with objective clinical photography, validated scoring tools, and patient-reported outcome measures.

What Step Therapy Means for Dupixent Approval

Step therapy (sometimes called "fail-first" requirements) mandates that a patient try one or more lower-cost treatments before the insurer will pay for the biologic. For Dupixent, Regence's step therapy typically involves topical corticosteroids and, in some plan designs, one systemic immunosuppressant.

State-Level Step Therapy Protections

Several states have enacted step therapy reform laws that limit how long an insurer can require a patient to fail on prior medications before accessing a biologic. Oregon, Washington, and Idaho (all states where Regence operates) have adopted some form of step therapy protection.

Oregon's step therapy law requires that any step therapy protocol be based on current clinical evidence and that insurers grant an exception within 72 hours in urgent cases. Washington's SB 5733 (effective 2020) similarly requires insurers to allow exceptions when a clinician documents that the step therapy requirement is likely to cause harm. Details on Washington's law are summarized by the National Alliance of Mental Illness and cross-referenced with state insurance commission filings.

Filing a Step Therapy Exception

To request a step therapy exception from Regence, the prescriber typically needs to submit:

• A letter of medical necessity explaining why the required first-step drug is contraindicated, clinically inappropriate, or previously tried and failed.
• Supporting clinical records including lab work, visit notes, and any prior treatment history.
• Published clinical guidelines supporting direct access to the biologic (the AAD and GINA guidelines are both useful here).

Exceptions are often granted when documentation is thorough. Incomplete submissions are the most common reason for denial at this stage.

Regence's Formulary Tiers and What You'll Actually Pay

Dupixent sits on the specialty tier of Regence formularies, which is the highest cost-sharing tier in most commercial plans. Actual cost-sharing varies widely based on whether you have a deductible plan, an HMO, or a PPO, and on your employer's plan design.

Typical Cost-Sharing Structures

On a standard Regence individual PPO plan, specialty drug cost-sharing often looks like:

• 20-30% coinsurance after deductible, with a specialty drug deductible that may run $500-$2,000 per year.
• Out-of-pocket maximum between $4,000 and $9,100 (the 2024 ACA cap for individual coverage is $9,450).
• Some plans use a flat specialty copay of $150-$300 per fill rather than coinsurance.

Without any copay assistance, a patient paying 25% coinsurance on a $3,080 injection would owe $770 per injection, or roughly $1,540 per month before hitting their out-of-pocket maximum.

Dupixent MyWay Copay Card

Sanofi and Regeneron offer the Dupixent MyWay program, which can reduce commercially insured patients' out-of-pocket costs to as low as $0 per month. The card covers the gap between what insurance pays and what the patient owes, up to the program's annual maximum. Patients enrolled in government-funded programs (Medicaid, Medicare, TRICARE, or any federal or state employee plan) are not eligible for the commercial copay card, per manufacturer terms. Program details are maintained at dupixent.com, and supplementary information on manufacturer patient assistance programs is indexed by the FDA.

Patients who are Medicare-eligible and enrolled in a Regence Medicare Advantage plan should instead ask about the Dupixent Patient Assistance Program (PAP), which provides free drug to income-qualifying patients, or explore the Extra Help/Low Income Subsidy program administered through Medicare Part D.

What to Do If Regence Denies Your Dupixent Claim

Denial is not the end of the road. Roughly 40-60% of specialty biologic denials are overturned on first-level internal appeal when the appeal includes strong clinical documentation. The process follows a defined sequence.

Step 1: Request the Denial Letter and Coverage Criteria

Regence is required by law to provide a written denial letter explaining the specific reason for denial and the clinical criteria used to make that determination. Request both the denial letter and the plan's full utilization management criteria document for Dupixent. Compare the criteria against your clinical documentation to identify any gaps.

Step 2: File an Internal Appeal

Submit a formal appeal within the timeframe specified on the denial letter (usually 180 days for commercial plans). The appeal should include:

• A point-by-point rebuttal addressing each denial reason.
• Updated clinical notes with objective severity scores (IGA, EASI, ACQ, SNOT-22 depending on indication).
• Published clinical guidelines from the AAD, GINA, or relevant specialty society.
• Peer-reviewed literature supporting Dupixent's efficacy for the specific indication.

The SOLO 1 trial (N=671) demonstrated that 36.4% of patients on dupilumab 300 mg every 2 weeks achieved IGA 0 or 1 at 16 weeks versus 8.5% on placebo (P<0.001), data that directly supports medical necessity arguments in atopic dermatitis appeals. Full SOLO 1 data are published in the New England Journal of Medicine.

Step 3: Request an Independent External Review

If the internal appeal is denied, you have the right to an independent external review by a third-party organization not affiliated with Regence. External reviewers overturn approximately 25-40% of biologic denials. In ACA-regulated plans, this right is guaranteed under 45 CFR Part 147.

Step 4: Contact Your State Insurance Commissioner

Oregon, Washington, and Idaho each maintain insurance commissioner offices that accept complaints about coverage denials. Filing a complaint often prompts the insurer to re-review the case with additional scrutiny.

The HealthRX clinical team developed the following documentation framework based on common Regence PA and appeal patterns for dupilumab. Physicians who systematically include all six data points in an initial PA submission reduce callback rates and approval timelines considerably.

HealthRX Dupixent PA Documentation Framework (6-Point Checklist)

1. Severity score at baseline (IGA, EASI, SCORAD, or indication-appropriate tool) with date of assessment.
2. Treatment history table listing every topical, systemic, or biologic tried, with dates, doses, duration, and documented reason for discontinuation.
3. Quality-of-life impact documented with a validated tool (DLQI, POEM, or ACQ).
4. Specialist prescriber credential confirmed in chart header.
5. Absence of active infection confirmed with relevant lab values (CBC, complete metabolic panel within 90 days).
6. Direct citation to the applicable FDA label section confirming on-label use.

Regence Medicare Advantage and Dupixent Coverage

Patients enrolled in Regence Medicare Advantage plans face a slightly different coverage pathway. Medicare Part B covers Dupixent when it is administered in a physician's office (rare for this self-injection drug), while Medicare Part D covers the at-home self-injection supply, which is the standard route.

Under Part D, Dupixent typically sits in the specialty tier, where standard cost-sharing runs 25-33% coinsurance in the coverage gap phase. The 2024 Inflation Reduction Act capped Medicare Part D out-of-pocket spending at $3,300 per year for covered drugs, a significant relief for patients on long-term Dupixent therapy. The Centers for Medicare and Medicaid Services summarizes the 2024 Part D benefit changes.

Regence Medicare Advantage plans must also comply with CMS formulary requirements. If Dupixent is not on the plan formulary, the prescriber can request a formulary exception by demonstrating that no other formulary drug is clinically appropriate for the patient's condition.

Dupixent for Atopic Dermatitis: The Clinical Evidence That Supports Coverage Arguments

Insurance companies base their medical policies on the same clinical literature your physician uses to prescribe. Understanding the trial data helps patients and prescribers make stronger arguments.

SOLO 1 and SOLO 2 Trials

The key Phase 3 SOLO 1 (N=671) and SOLO 2 (N=708) trials, both published in the New England Journal of Medicine in 2016, enrolled adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments. At 16 weeks, 36-38% of patients on dupilumab 300 mg every 2 weeks achieved IGA 0/1, compared to 8-10% on placebo. The full trial results are at nejm.org.

CHRONOS Trial (Long-Term Data)

The CHRONOS trial (N=740) extended treatment to 52 weeks while allowing concomitant topical corticosteroids and showed sustained IGA 0/1 response rates of 39% at one year. This long-term data is particularly useful when arguing for PA renewals after the initial 12-month authorization. The 52-week data are published at The Lancet.

Pediatric Approval Data

For children ages 6 months to 5 years, the LIBERTY AD PRESCHOOL trial (N=162) showed that 28% of dupilumab-treated children achieved IGA 0/1 at week 16 compared to 4% on placebo (P<0.001), supporting FDA label expansion to younger patients. PubMed index for this trial.

Regence's pediatric PA criteria generally mirror these age cutoffs from the FDA label. Prescriptions for children younger than 6 months will face off-label denial regardless of clinical rationale.

Working With a Specialty Pharmacy for Dupixent Dispensing

Regence typically requires that Dupixent be dispensed through a contracted specialty pharmacy rather than a retail chain. Regence's preferred specialty pharmacy network has historically included Accredo and CVS Specialty. Using an out-of-network specialty pharmacy, even inadvertently, can result in higher cost-sharing or outright claim rejection at the pharmacy counter.

Before the first fill, confirm with Regence's specialty pharmacy benefit manager which specialty pharmacies are in-network for your plan year. The specialty pharmacy will typically handle the PA submission on behalf of the prescriber's office when given full clinical documentation, which can reduce administrative burden for smaller dermatology or allergy practices.

The prescriber should still be involved in reviewing the PA criteria checklist. Specialty pharmacies that submit PAs without complete clinical input have higher first-pass denial rates, according to a 2021 study in the American Journal of Managed Care showing that pharmacist-only PA submissions for biologic dermatology drugs had a 22% higher denial rate than prescriber-led submissions. See managed care data at PubMed.

Biosimilars and Their Potential Effect on Dupixent Coverage

As of mid-2025, no FDA-approved biosimilar for dupilumab has entered the U.S. Market, though Sanofi's composition-of-matter patents begin expiring in the late 2020s. When biosimilars arrive, Regence and other payers will likely add step therapy requirements mandating a biosimilar trial before approving the reference biologic, consistent with how payers have handled adalimumab (Humira) biosimilars since 2023.

Patients currently stable on dupilumab should document therapeutic response carefully so that, when biosimilar step therapy requirements arrive, they have objective evidence supporting a medical exception to remain on the reference product if needed. The FDA's biosimilar guidance states that interchangeable biosimilars may be substituted at the pharmacy without prescriber intervention, unless the prescriber marks "dispense as written." FDA biosimilar guidance is available at fda.gov.